These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 6376031)

  • 1. Cellular loci of sulfonylurea actions.
    Lebovitz HE
    Diabetes Care; 1984; 7 Suppl 1():67-71. PubMed ID: 6376031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfonylurea effects on target tissues for insulin.
    McCaleb ML; Maloff BL; Nowak SM; Lockwood DH
    Diabetes Care; 1984; 7 Suppl 1():42-6. PubMed ID: 6376028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family.
    Malaisse WJ
    Horm Metab Res; 1995 Jun; 27(6):263-6. PubMed ID: 7557835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitus.
    Beck-Nielsen H; Hjøllund E; Pedersen O; Richelsen B; Sørensen NS
    Diabetes Care; 1984; 7 Suppl 1():100-5. PubMed ID: 6428842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Porin proteins in mitochondria from rat pancreatic islet cells and white adipocytes: identification and regulation of hexokinase binding by the sulfonylurea glimepiride.
    Müller G; Korndörfer A; Kornak U; Malaisse WJ
    Arch Biochem Biophys; 1994 Jan; 308(1):8-23. PubMed ID: 8311478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB
    Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of chronic tolbutamide administration on normal and obese-hyperglycemic mice: evidence for post-receptor potentiation of insulin action.
    Poyet C; Feldman JM
    Res Commun Chem Pathol Pharmacol; 1982 Mar; 35(3):355-76. PubMed ID: 7043679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of glurenorm on immunohistochemical changes in pancreatic beta cells of rats in experimental diabetes.
    Koyuturk M; Ozsoy-Sacan O; Bolkent S; Yanardag R
    Indian J Exp Biol; 2005 Mar; 43(3):268-71. PubMed ID: 15816415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas.
    Müller G; Satoh Y; Geisen K
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S115-37. PubMed ID: 8529504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man.
    Pfeifer MA; Halter JB; Judzewitsch RG; Beard JC; Best JD; Ward WK; Porte D
    Diabetes Care; 1984; 7 Suppl 1():25-34. PubMed ID: 6376026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of glucagon secretion.
    Young A
    Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment.
    Kawai J; Ohara-Imaizumi M; Nakamichi Y; Okamura T; Akimoto Y; Matsushima S; Aoyagi K; Kawakami H; Watanabe T; Watada H; Kawamori R; Nagamatsu S
    Biochem J; 2008 May; 412(1):93-101. PubMed ID: 18254725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose concentration-dependent potentiation of insulin secretion by a new chemical entity, KCP256.
    Mori K; Takasaki K; Katoh Y; Yano H; Ueno K; Ichimura M; Kusaka H; Nomoto Y; Higo K; Nakanishi S
    Eur J Pharmacol; 2005 Dec; 528(1-3):176-82. PubMed ID: 16316644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes.
    Kolterman OG; Olefsky JM
    Diabetes Care; 1984; 7 Suppl 1():81-8. PubMed ID: 6376033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of repaglinide upon nutrient metabolism, biosynthetic activity, cationic fluxes and insulin release in rat pancreatic islets.
    Louchami K; Jijakli H; Sener A; Malaisse WJ
    Res Commun Mol Pathol Pharmacol; 1998 Feb; 99(2):155-68. PubMed ID: 9583090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the effects of sulfonylurea exposure on pancreatic beta cell metabolism.
    Brennan L; Hewage C; Malthouse JP; McClenaghan NH; Flatt PR; Newsholme P
    FEBS J; 2006 Nov; 273(22):5160-8. PubMed ID: 17054712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Extrapancreatic effects of sulfonylurea compounds. IV. Increase of the effect of insulin due to tolbutamide, glibornuride, and glibenclamide in vitro].
    Beyer J; Gather W; Schöffling K
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2179. PubMed ID: 4198966
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of glipizide on the insulin production by isolated mouse pancreatic islets.
    Andersson A; Borg LA
    Acta Endocrinol Suppl (Copenh); 1980; 239():37-41. PubMed ID: 7001842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mode of action of oral antidiabetic drugs].
    Frey H
    Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1591-5. PubMed ID: 4588814
    [No Abstract]   [Full Text] [Related]  

  • 20. [Current concepts of the pancreatic and extrapancreatic mechanisms of the action of peroral hypoglycemic sulfonylurea preparations].
    Poltorak VV; Gladkikh AI
    Probl Endokrinol (Mosk); 1985; 31(2):76-85. PubMed ID: 2859589
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.